144 related articles for article (PubMed ID: 36334881)
1. Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy.
Scarini JF; Lavareze L; de Lima-Souza RA; Emerick C; Gonçalves MT; Figueiredo-Maciel T; Vieira GS; Kimura TC; de Sá RS; Aquino IG; Fernandes PM; Kowalski LP; Altemani A; Mariano FV; Egal ESA
Crit Rev Oncol Hematol; 2022 Dec; 180():103863. PubMed ID: 36334881
[TBL] [Abstract][Full Text] [Related]
2. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
Sola AM; Johnson DE; Grandis JR
Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
[TBL] [Abstract][Full Text] [Related]
3. Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z; Grandis JR; Johnson DE
Expert Opin Emerg Drugs; 2022 Sep; 27(3):333-344. PubMed ID: 36131561
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
5. How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics.
Jain AP; Radhakrishnan A; Pinto S; Patel K; Kumar M; Nanjappa V; Raja R; Keshava Prasad TS; Mathur PP; Sidransky D; Chatterjee A; Gowda H
OMICS; 2021 Sep; 25(9):605-616. PubMed ID: 34432535
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
8. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
9. An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.
Lenze N; Chera B; Sheth S
Expert Opin Pharmacother; 2021 Feb; 22(2):135-144. PubMed ID: 33121281
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer: A Review.
Ritter A; Koirala N; Wieland A; Kaumaya PTP; Mitchell DL
JAMA Otolaryngol Head Neck Surg; 2023 Feb; 149(2):168-176. PubMed ID: 36580281
[TBL] [Abstract][Full Text] [Related]
13. Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.
Kitamura N; Sento S; Yoshizawa Y; Sasabe E; Kudo Y; Yamamoto T
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383632
[TBL] [Abstract][Full Text] [Related]
14. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.
Ausoni S; Boscolo-Rizzo P; Singh B; Da Mosto MC; Spinato G; Tirelli G; Spinato R; Azzarello G
Cancer Metastasis Rev; 2016 Sep; 35(3):413-26. PubMed ID: 27194534
[TBL] [Abstract][Full Text] [Related]
15. New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.
Bensen R; Brognard J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799513
[TBL] [Abstract][Full Text] [Related]
16. Current Role of Dacomitinib in Head and Neck Cancer.
Elicin O; Ozsahin M
Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
[TBL] [Abstract][Full Text] [Related]
17. A new gamboge derivative compound 2 inhibits cancer stem-like cells via suppressing EGFR tyrosine phosphorylation in head and neck squamous cell carcinoma.
Deng R; Wang X; Liu Y; Yan M; Hanada S; Xu Q; Zhang J; Han Z; Chen W; Zhang P
J Cell Mol Med; 2013 Nov; 17(11):1422-33. PubMed ID: 24112466
[TBL] [Abstract][Full Text] [Related]
18. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
Park R; Park JC
Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.
Blaszczak W; Barczak W; Wegner A; Golusinski W; Suchorska WM
Med Oncol; 2017 Apr; 34(4):60. PubMed ID: 28315228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
